Humanized genO-CT26-hCD47-LZ reporter tumor cell line

Validation data

• genO-CT26-hCD47-LZ cells homogeneously express human CD47 in vitro

  Expression analysis by flow cytometry. Human CD47 expression was assessed in CT26 parental cell line (left) and in genO-CT26-hCD47-LZ cell line (right).

  

• genO-CT26-hCD47-LZ cells form tumors in vivo

  BALB/c mice (n=6) were injected (s.c.) with 1x10⁶ genO-CT26-hCD47-LZ cells. Tumor growth was measured every 2 to 3 days. Tumor size (mm³) = (width²*length)/2

  ‍

  

• Most genO-CT26-hCD47-LZ tumor cells express human CD47 at late point

  BALB/c mice were injected (s.c.) with 1x10⁶ genO-CT26-hCD47-LZ cells. Two 1000mm³ tumors were collected and human and murine CD47 expression was assessed by flow cytometry upon gating on ZsGreen⁺ / CD45^- live cells.

  ‍

  

• genO-CD26-hCD47-LZ tumors are infiltrated

  BALB/c mice were injected (s.c.) with 1x10⁶ genO-CT26-hCD47-LZ cells. Two 1000mm³ tumor were collected and tumor composition was determined by flow cytometry. Immune populations were assessed by flow cytometry on mCD45⁺, CD3⁺ (T cells), mCD45⁺, CD11b⁺, CD11c^-, F4/80^- (Monocytes), mCD45⁺, CD11b⁺, CD11b^-, F4/80⁺ (Macrophages), mCD45⁺, CD11b⁺, CD11c⁺ (DC cells) and mCD45⁺, CD3^- Nkp46⁺ (NK cells).

  

• genO-CD26-hCD47-LZ tumors are infiltrated

  BALB/c mice were injected (s.c.) with 1x10⁶ genO-CT26-hCD47-LZ cells. Two 1000mm³ tumor were collected and tumor composition was determined by flow cytometry. Immune populations were assessed by flow cytometry on mCD45⁺, CD3⁺ (T cells), mCD45⁺, CD11b⁺, CD11c^-, F4/80^- (Monocytes), mCD45⁺, CD11b⁺, CD11b^-, F4/80⁺ (Macrophages), mCD45⁺, CD11b⁺, CD11c⁺ (DC cells) and mCD45⁺, CD3^- Nkp46⁺ (NK cells).

  

• genO-CD26-hCD47-LZ tumors are infiltrated

  BALB/c mice were injected (s.c.) with 1x10⁶ genO-CT26-hCD47-LZ cells. Two 1000mm³ tumor were collected and tumor composition was determined by flow cytometry. Immune populations were assessed by flow cytometry on mCD45⁺, CD3⁺ (T cells), mCD45⁺, CD11b⁺, CD11c^-, F4/80^- (Monocytes), mCD45⁺, CD11b⁺, CD11b^-, F4/80⁺ (Macrophages), mCD45⁺, CD11b⁺, CD11c⁺ (DC cells) and mCD45⁺, CD3^- Nkp46⁺ (NK cells).

  

• genO-CD26-hCD47-LZ tumors are infiltrated

  BALB/c mice were injected (s.c.) with 1x10⁶ genO-CT26-hCD47-LZ cells. Two 1000mm³ tumor were collected and tumor composition was determined by flow cytometry. Immune populations were assessed by flow cytometry on mCD45⁺, CD3⁺ (T cells), mCD45⁺, CD11b⁺, CD11c^-, F4/80^- (Monocytes), mCD45⁺, CD11b⁺, CD11b^-, F4/80⁺ (Macrophages), mCD45⁺, CD11b⁺, CD11c⁺ (DC cells) and mCD45⁺, CD3^- Nkp46⁺ (NK cells).

  

• genO-CD26-hCD47-LZ tumors are infiltrated

  BALB/c mice were injected (s.c.) with 1x10⁶ genO-CT26-hCD47-LZ cells. Two 1000mm³ tumor were collected and tumor composition was determined by flow cytometry. Immune populations were assessed by flow cytometry on mCD45⁺, CD3⁺ (T cells), mCD45⁺, CD11b⁺, CD11c^-, F4/80^- (Monocytes), mCD45⁺, CD11b⁺, CD11b^-, F4/80⁺ (Macrophages), mCD45⁺, CD11b⁺, CD11c⁺ (DC cells) and mCD45⁺, CD3^- Nkp46⁺ (NK cells).